What is the newest treatment for sinusitis in adults, particularly for chronic rhinosinusitis with nasal polyps?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Newest Treatment for Sinusitis

For adults with chronic rhinosinusitis with nasal polyps (CRSwNP), biologics—particularly tezepelumab and dupilumab—represent the newest and most effective treatments, with tezepelumab showing the most recent breakthrough efficacy in 2025.

Biologic Therapies: The Current Standard for Severe CRSwNP

The landscape of CRSwNP treatment has fundamentally shifted with FDA-approved biologics now available for patients who fail medical management. Four biologics are currently FDA-approved: dupilumab, omalizumab, mepolizumab, and tezepelumab 1. These target type 2 inflammatory pathways that drive nasal polyp formation.

Tezepelumab: The Most Recent Addition

Tezepelumab (anti-TSLP) demonstrated remarkable efficacy in the 2025 WAYPOINT trial 2:

  • Reduced nasal polyp scores by 2.07 points more than placebo (P<0.001)
  • Reduced nasal congestion by 1.03 points (P<0.001)
  • Only 0.5% required surgery versus 22.1% on placebo (hazard ratio 0.02)
  • Only 5.2% needed systemic steroids versus 18.3% on placebo (hazard ratio 0.12)
  • Improved smell, quality of life (SNOT-22), and CT scores significantly

This represents the strongest recent evidence for any single biologic in severe CRSwNP.

Comparative Efficacy of Biologics

A 2026 network meta-analysis comparing eight monoclonal antibodies found 3:

  • Stapokibart (anti-IL-4Rα) ranked first for reducing nasal polyp size
  • Dupilumab led in improving quality of life (SNOT-22 scores)
  • Both dupilumab and stapokibart improved smell (UPSIT scores)
  • All biologics showed comparable safety to placebo

Real-world evidence from 2025-2026 confirms that biologics outperform their clinical trial results in actual practice, with dupilumab showing particularly notable effects 4.

Treatment Algorithm Based on Current Guidelines

Step 1: Verify Diagnosis and Assess Candidacy

Before considering any advanced therapy, confirm the patient meets diagnostic criteria 5:

  • Symptoms lasting >12 weeks: nasal obstruction, thick drainage, smell loss, facial pressure
  • Objective evidence on nasal endoscopy or CT imaging
  • Do NOT require a predefined duration of medical therapy as prerequisite to biologics 5

Step 2: Identify Patients Who Benefit Most from Biologics

Prioritize biologics for patients with 6, 5:

  • CRSwNP with polyps showing bony erosion
  • Eosinophilic mucin present
  • Comorbid asthma (especially severe/uncontrolled)
  • Aspirin-exacerbated respiratory disease (AERD)
  • Failed prior endoscopic sinus surgery
  • Recurrent disease requiring systemic steroids

Step 3: First-Line Medical Management

Intranasal corticosteroids (INCS) remain foundational for all CRSwNP patients 6. However, do NOT delay biologics in severe cases waiting for arbitrary medical therapy trials.

Step 4: Biologic Selection

For severe, uncontrolled CRSwNP:

  • Tezepelumab 210 mg subcutaneously every 4 weeks is the newest option with strongest recent evidence 2
  • Dupilumab shows excellent real-world efficacy, particularly for quality of life 3, 4
  • Consider patient-specific factors: comorbid asthma, AERD, insurance coverage

Step 5: Aspirin Therapy After Desensitization (ATAD)

For AERD patients specifically, aspirin therapy following desensitization is an additional option 6. This applies only to the AERD subtype, not general CRSwNP.

Critical Pitfalls to Avoid

Do NOT:

  • Prescribe antibiotics without significant purulent discharge on examination 5
  • Require arbitrary durations of failed medical therapy before offering biologics 5
  • Plan surgery extent solely on CT mucosal thickening criteria 5
  • Delay biologics in patients with clear indications (polyps with bony erosion, eosinophilic disease, recurrent disease)

DO:

  • Counsel patients that CRSwNP is chronic with no cure; biologics require long-term management 5
  • Set realistic expectations about potential for relapse 5
  • Obtain fine-cut CT for surgical planning if surgery considered 5

Real-World Impact

Big data analysis from 2026 shows biologics significantly reduce 7:

  • Antibiotic use
  • Systemic steroid requirements
  • Emergency room visits and hospitalizations
  • Revision surgery rates
  • Overall healthcare utilization

The evidence strongly supports biologics as disease-modifying therapy that reduces both symptom burden and healthcare costs in severe CRSwNP 7.

References

5
Guideline

clinical practice guideline: surgical management of chronic rhinosinusitis.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2025

Related Questions

In a patient with chronic rhinosinusitis who has persistent symptoms despite maximal medical therapy and evidence of type‑2 inflammation, what are the indications for initiating biologic therapy, which biologics are recommended, their dosing regimens, and how should response be monitored?
What is the comparison between Dupixent (dupilumab) and Tezspire (tezepelumab) for treating nasal polyps?
What is the FDA approval status of Tezspire (tezepelumab) for chronic rhinosinusitis with nasal polyps?
Is it okay to take my Airsupra (inhaler) daily with dupilumab (dupilumab) for my severe asthma and chronic rhinosinusitis with nasal polyps?
What is the comparative efficacy and safety of dupilumab (Dupixent) vs mepolizumab (Nucala) and omalizumab (Xolair) in chronic rhinosinusitis with nasal polyps (CRSwNP)?
How is epinephrine administered during cardiopulmonary resuscitation (CPR)?
What is the gold‑standard test for diagnosing active pulmonary tuberculosis—chest X‑ray, Mantoux tuberculin skin test, or another method? And if a patient with Addison’s disease does not have tuberculosis as the cause, how should the evaluation and management differ without active pulmonary TB?
What is the recommended algorithm for managing persistent vomiting of enteral tube feeds in a mechanically ventilated patient?
What is the appropriate evaluation and management for burning and tingling of the vagina not associated with urination in a perimenopausal woman?
Should levothyroxine (synthetic thyroxine) and Lip‑thyroxin (levothyroxine) be prescribed together?
What antidepressant should be tried next in a 33‑year‑old patient with a PHQ‑9 score of 9 who failed sertraline (Zoloft) 100 mg and escitalopram (Lexapro) due to a major breakdown, after pharmacogenomic testing?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.